Safety of dupilumab in patients with atopic dermatitis: expert opinion.

Expert Opinion on Drug Safety
Wojciech FrancuzikMargitta Worm

Abstract

Introduction: Dupilumab, the first biologic drug to be approved for the treatment of moderate to severe atopic dermatitis in adolescents and adults, has shown efficacy and safety in clinical trials. Data on long-term safety is limited but crucial for pharmacovigilance. Therefore, we performed this review to evaluate available real-world data on the long-term safety of dupilumab in atopic dermatitis.Areas covered: PubMed and Google Scholar databases were searched for randomized controlled clinical trials (RCTs), observational studies, case series, and case reports regarding the use of dupilumab for the treatment of atopic dermatitis. Adverse events were summarized and critically evaluated.Expert opinion: Atopic dermatitis patients receiving dupilumab reported ocular surface disease more often than patients receiving placebo. Real-world data show previously unreported adverse events (blood eosinophilia, rosacea-like skin lesions, weight gain), but their mechanistic association to dupilumab treatment still requires clarification. Cutaneous T-cell lymphomas occurring under the therapy with dupilumab might be unrelated to the drug use itself but long-term follow-up data of large patient cohorts is necessary to rule out such possibil...Continue Reading

References

Nov 16, 2002·Progress in Retinal and Eye Research·Darlene A Dartt
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
May 22, 2013·The New England Journal of Medicine·Sally WenzelGianluca Pirozzi
Jul 2, 2015·Investigative Ophthalmology & Visual Science·Johanna Tukler HenrikssonStephen C Pflugfelder
Feb 3, 2016·JAMA : the Journal of the American Medical Association·Claus BachertE Rand Sutherland
Jun 14, 2016·BioMed Research International·Ieva SauliteUlrike Wehkamp
Oct 4, 2016·The New England Journal of Medicine·Eric L SimpsonUNKNOWN SOLO 1 and SOLO 2 Investigators
Oct 16, 2016·Journal of the American Academy of Dermatology·Yuki M F AndersenJacob P Thyssen
Jun 12, 2017·Journal of the American Academy of Dermatology·Jacob P ThyssenAlexander Egeberg
Oct 11, 2017·Journal of the American Academy of Dermatology·Patrick Fleming, Aaron M Drucker
Nov 29, 2017·International Immunopharmacology·Zuzhen OuWeikang Zhou
Dec 21, 2017·American Journal of Ophthalmology Case Reports·Alexander C BarnesJulian D Perry
Feb 2, 2018·JAAD Case Reports·Krystal Mitchell, Jacob Levitt
Feb 13, 2018·The Journal of Allergy and Clinical Immunology. in Practice·Andreas WollenbergMarjolein de Bruin-Weller
Feb 24, 2018·Journal of the American Academy of Dermatology·Melinda J GooderhamKim A Papp
May 2, 2018·The British Journal of Dermatology·A-S DarrigadeJ Seneschal
May 22, 2018·The New England Journal of Medicine·Mario CastroAriel Teper
May 22, 2018·The New England Journal of Medicine·Klaus F RabeAriel Teper
Aug 22, 2018·JAAD Case Reports·Elisabeth H TraceyAlok Vij
Dec 12, 2018·Journal of Investigational Allergology & Clinical Immunology·B Barroso-GarcíaJ Sastre
Dec 12, 2018·Clinical and Experimental Dermatology·I Salgüero-FernándezG Roustan-Gullón
Dec 19, 2018·JAAD Case Reports·Kathleen FlanaganJanet Lin
Mar 3, 2019·Journal of the American Academy of Dermatology·Sarah FaizUNKNOWN Groupe de Recherche sur l'Eczéma aTopique (GREAT), France
Mar 6, 2019·Dermatologic Therapy·Nolan J MaloneyKyle Cheng
Mar 10, 2019·The British Journal of Dermatology·B AkinladeA Wollenberg
Mar 16, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·M SevrayC Abasq-Thomas
Apr 3, 2019·Acta Dermato-venereologica·Hideaki UchidaYayoi Tada
Apr 25, 2019·The British Journal of Dermatology·Z N WillsmoreA E Pink
May 28, 2019·The Journal of Dermatological Treatment·Haley D HeibelVivian Y Shi
Jun 24, 2019·Ophthalmology and Therapy·Adrien MaudinetThi Ha Chau Tran
Jul 17, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·L LudriksoneS Schliemann
Jul 20, 2019·Clinical and Experimental Dermatology·L E M de WijsD J Hijnen
Oct 15, 2019·Dermatitis : Contact, Atopic, Occupational, Drug·Molly StoutJonathan I Silverberg
Oct 28, 2019·The Journal of Dermatological Treatment·M C FargnoliUNKNOWN Dupilumab Italian National Access Program (Dup-INAP group)
Oct 31, 2019·Dermatologic Therapy·Maddalena NapolitanoCataldo Patruno
Nov 5, 2019·JAAD Case Reports·Fleur S A de BeerMarjolein S de Bruin-Weller
Jan 1, 2020·The Journal of Dermatological Treatment·Debora H LeeJeremiah P Tao
Jan 28, 2020·Cornea·Paulina LibermanMeghan Berkenstock
Feb 26, 2020·JAAD Case Reports·Aakaash Varma, Jacob Levitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.